林业发展局发出30封警告函,警告远程保健公司不实销售未经批准的复合药物,相当于林业发展局核准的治疗。 FDA issues 30 warning letters against telehealth firms for falsely marketing unapproved compounded drugs as equivalent to FDA-approved treatments.

美国食品和药物管理局加强了对未经批准的复合药物的执法,发出30封新的警告信,针对远程医疗公司进行误导营销,包括错误地声称复合GLP-1和产品等同于FDA批准的药物. The FDA has stepped up enforcement against unapproved compounded drugs, issuing 30 new warning letters targeting telehealth companies for misleading marketing, including falsely claiming compounded GLP-1 and peptide products are equivalent to FDA-approved drugs. 美国联邦卫生局正在打击违反联邦法律的品牌名称和"通用"声明, 特别针对人类消费的研究用途的滥用. The agency is cracking down on the use of brand names and "generic" claims, which violate federal law, and is specifically addressing the misuse of research-use-only peptides for human consumption. 这些行动是2025年9月开始的更广泛执法推动的一部分,旨在保护消费者免受欺骗性广告的危害,并确保未经批准的产品不被当作合法核准的药物的安全或有效替代品。 These actions, part of a broader enforcement push starting in September 2025, aim to protect consumers from deceptive advertising and ensure unapproved products are not presented as safe or effective alternatives to legally approved medications.